Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial

The Lancet Oncology

Volumn 16, Issue 3, 2015, Pages 257-265

  Rizvi, Naiyer A ^a   Mazières, Julien ^b   Planchard, David ^c   Stinchcombe, Thomas E ^d   Dy, Grace K ^e   Antonia, Scott J ^f   Horn, Leora ^g   Lena, Hervé ^h   Minenza, Elisa ⁱ   Mennecier, Bertrand ^j   Otterson, Gregory A ^k   Campos, Luis T ^l   Gandara, David R ^m   Levy, Benjamin P ⁿ   Nair, Suresh G ^o   Zalcman, Gérard ^p   Wolf, Jürgen ^q   Souquet, Pierre Jean ^r   Baldini, Editta ^s   Cappuzzo, Federico ^t   Chouaid, Christos ^u   Dowlati, Afshin ^v   Sanborn, Rachel ^w   Lopez Chavez, Ariel ^x   Grohe, Christian ^y   Huber, Rudolf M ^z   Harbison, Christopher T ^aa   Baudelet, Christine ^aa   Lestini, Brian J ^aa   Ramalingam, Suresh S ^ab   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SERVICE DE PNEUMOLOGIE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ S MARIA HOSPITAL   (Italy)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^l PAS   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ BETH ISRAEL MEDICAL CENTER   (United States)

^o LEHIGH VALLEY HOSPITAL   (United States)

^p CAEN UNIVERSITY HOSPITAL   (France)

^q UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^r CENTRE HOSPITALIER LYON SUD   (France)

^s CAMPO DI MARTE HOSPITAL   (Italy)

^t ISTITUTO TOSCANO TUMORI   (Italy)

^u CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^v UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^w PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^x UNIVERSITY OF MIAMI   (United States)

^y Evangelische Lungenklinik Berlin   (Germany)

^z LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^aa BRISTOL MYERS SQUIBB   (United States)

^ab EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G4; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BRAIN ISCHEMIA; CANCER CENTER; CANCER PATIENT; CAUSE OF DEATH; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG ACTIVITY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FRANCE; GERMANY; HOSPITAL; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SINGLE BLIND PROCEDURE; SQUAMOUS CELL LUNG CARCINOMA; UNITED STATES; VOMITING; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; EUROPE; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; TIME; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; RISK FACTORS; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84924901863     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70054-9     Document Type: Article

References (35)

1. Domingues D, Turner A, Dilla Silva M Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy 2014, 6:1221-1235.
2. Schreiber RD, Old LJ, Smyth MJ Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
3. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
4. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
5. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
6. Brahmer JR, Horn L, Antonia S, et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2012, 30:7509. (abstr).
7. Gettinger SN, Horn L, Gandhi L, et al. Long-term survival, clinical activity, and safety of nivolumab (anti-PD-1; BMS-936558, ONO-4538) in patients (Pts) with advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol 2014, 90:3428. (abstr).
8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
9. Travis WD Pathology of lung cancer. Clin Chest Med 2011, 32:669-692.
10. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004, 59:828-836.
11. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625. NSCLC Meta-Analyses Collaborative Group.
12. Penrod JR, Korytowsky B, Petrilla A, et al. Survival of U.S. Medicare patients with advanced non-small cell lung cancer by line of therapy. Proc Am Soc Clin Oncol 2014, 32:6582. (abstr).
13. Scartozzi M, Mazzanti P, Giampieri R, et al. Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: selecting the unselectable?. Lung Cancer 2010, 68:433-437.
14. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003, 39:55-61.
15. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
16. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, Version 4.0. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services (accessed Dec 18, 2014). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
18. Clopper C, Pearson ES The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26:404-413.
19. Brookmeyer R, Crowley J A confidence interval for the median survival time. Biometrics 1982, 38:29-41.
20. Greenwood M. The natural duration of cancer. Reports on Public Health and Medical Subjects 1926; 33: 1-26. London: HM Stationery Office.
21. Hodi S, O'Day S, McDermott D, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
22. Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). Proc Am Soc Clin Oncol 2013, 31:3016. (abstr).
23. Topalian SL, Sznol M, Brahmer JR, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial. J Clin Oncol 2013, 31:3002. (abstr).
24. Powderly JD, Koeppen H, Hodi FS, et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. Proc Am Soc Clin Oncol 2013, 31:3001. (abstr).
25. Taube JM, Klein AP, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014, 20:5064-5074.
26. Garon EB, Gandhi L, Rizvi N, et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol 2014, 25:LBA43. (abstr).
27. Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2014, 32:8007. (abstr).
28. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science Transl Med 2012, 4:127ra37.
29. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
30. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
31. Iressa (gefitinib) US prescribing information, NDA 21-399/S-008,2004 (accessed Dec 17, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001016/WC500036358.pdf.
32. Tarceva (erlotinib) US prescribing information (accessed Dec 17, 2014). http://www.gene.com/download/pdf/tarceva_prescribing.pdf.
33. Gemcitabine (Gemzar) US prescribing information (accessed Dec 17, 2014). http://pi.lilly.com/us/gemzar.pdf.
34. Grande C, Villanueva MJ, Huidobro G, Casal J Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol 2007, 9:578-581.
35. Schuette WHW, Gröschel A, Sebastian M, et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 2013, 14:215-233.